ArticleClinicoEconomics and outcomes research : CEOR2026

Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis.

Biao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.